Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ASTRAZENECA Latest News

21 HOURS AGO - Zero Hedge

A Must Read - Share

"Highway Robbery": Are Patients Paying For Biotech M&A Bubble?

It’s no secret that biotech has been on an incredible run over the past several years. In fact, as we pointed out late last month, it’s been the top performing sector for five years running, has outperformed the S&P by a count of 3.5:1, and is up four-fold since the dot-com bubble. Additionally, there were a record 82 IPOs in ...

Tags: "Highway Robbery": Are Patients Paying For Biotech M&A Bubble?,  Astrazeneca Latest News

APR 27, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca Falls on Q1 Earnings Decline, Reiterates View - Analyst Blog

AstraZeneca's (AZN) first-quarter 2015 core earnings came in at $1.08 per American Depositary Share, down 3% at constant exchange rate from the year-ago period.

Tags: AstraZeneca Falls on Q1 Earnings Decline, Reiterates View - Analyst Blog,  Astrazeneca Latest News

APR 26, 2015 - Business Insider

A Must Read - Share

UK government would oppose any takeover of BP: FT

(Reuters) - Britain's outgoing government has told BP Plc that it wants the company to remain a British industrial champion and it would oppose any takeover of the oil producer, the Financial Times reported.The message follows the $70 billion deal to acquire rival producer BG by oil major Royal Dutch Shell , which has sparked speculation of a larger wave ...

Tags: UK government would oppose any takeover of BP: FT,  Astrazeneca Latest News

APR 24, 2015 - The Independent

A Must Read - Share

Investors in pay revolt at AstraZeneca

The pharmaceutical giant AstraZeneca was hit by a pay revolt yesterday over long-term awards handed to its management team.

Tags: Investors in pay revolt at AstraZeneca,  Astrazeneca Latest News

APR 24, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog

AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.

Tags: AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog,  Astrazeneca Latest News